The enrichment of these anti-ACE2 IgMs in patients with severe disease, coupled with the ability of anti-ACE2 IgMs to both activate the classical complement cascade and modulate microvascular endothelial barrier properties, strongly suggests that they play a role in the angiocentric, complement-activating pathology observed in patients with severe COVID-19. The gene discussed is ACE2; the disease is COVID-19.